MEDI7352 is an experimental non-opioid analgesic drug that works as a bispecific monoclonal antibody against tumour necrosis factor (TNF) and nerve growth factor (NGF); it is developed by AstraZeneca for chronic pain.[1][2][3][4]
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Legal status | |
| Legal status |
|
References
edit- ^ "Late-stage pain pipeline refuses to swell". Evaluate.com. 26 April 2022. Retrieved 24 November 2023.
- ^ Conaghan, Philip G.; Cook, Andrew D.; Hamilton, John A.; Tak, Paul P. (June 2019). "Therapeutic options for targeting inflammatory osteoarthritis pain". Nature Reviews Rheumatology. 15 (6): 355–363. doi:10.1038/s41584-019-0221-y. ISSN 1759-4804. PMID 31068673. S2CID 148571144.
- ^ Alcaraz, María José; Guillén, María Isabel; Ferrándiz, María Luisa (July 2019). "Emerging therapeutic agents in osteoarthritis". Biochemical Pharmacology. 165: 4–16. doi:10.1016/j.bcp.2019.02.034. PMID 30826327. S2CID 73513526.
- ^ Zhao, Qi (April 2020). "Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date". BioDrugs. 34 (2): 111–119. doi:10.1007/s40259-019-00400-2. PMID 31916225. S2CID 210044512.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |